The medication violations in racehorses at Louisiana racetracks from 2016 to 2020

Analytical advances in horseracing medication and doping control from 2018 to 2023

The analytical approaches taken by laboratories to implement robust and efficient regulation of horseracing medication and doping control are complex and constantly evolving. Each laboratory's approach will be dictated by differences in regulatory, economic and scientific drivers specific to their local environment. However, in general, laboratories will all be undertaking developments and improvements to their screening strategies in order to meet new and emerging threats as well as provide improved service to their customers. In this paper, the published analytical advances in horseracing medication and doping control since the 22nd International Conference of Racing Analysts and Veterinarians will be reviewed. Due to the unprecedented impact of COVID-19 on the worldwide economy, the normal 2-year period of this review was extended to over 5 years. As such, there was considerable ground to cover, resulting in an increase in the number of relevant publications included from 107 to 307. Major trends in publications will be summarised and possible future directions highlighted. This will cover developments in the detection of 'small' and 'large' molecule drugs, sample preparation procedures and the use of alternative matrices, instrumental advances/applications, drug metabolism and pharmacokinetics, the detection and prevalence of 'endogenous' compounds and biomarker and OMICs approaches. Particular emphasis will be given to research into the potential threat of gene doping, which is a significant area of new and continued research for many laboratories. Furthermore, developments in analytical instrumentation relevant to equine medication and doping control will be discussed.

Survey on 9 years of anti-doping controls in horse races in Italy

BACKGROUND

Doping in racehorses is a threat to horse welfare and the integrity of the sport. Despite its relevance, the literature on the prevalence of anti-doping violations worldwide is limited.

OBJECTIVES

To analyse anti-doping violations in racehorses in Italy.

STUDY DESIGN

Retrospective observational study.

METHODS

Data on horse races, anti-doping testing, and confirmed violations between 2014 and 2022 were collected and analysed. Positivity rates, most common drug classes and parent drugs, and differences between trotting and galloping horses were investigated.

RESULTS

During the considered 9-year timeframe, the national laboratory analysed a total of 104,770 samples. A total of 536 horses were confirmed to be positive (92.8% positivity rate at second analysis). The average prevalence over the years was 0.48 ± 0.15% in trotters and 0.50 ± 0.15% in gallopers. Seventy-seven parent drugs, belonging to 29 different drug classes, were detected. The five most represented drug classes were steroidal anti-inflammatories (19.0%), stimulants (16.4%), NSAIDs (15.5%), anabolic steroids (9.9%) and sedatives (9.7%). The five most frequent substances were dexamethasone (8.4%), cocaine (7.1%), testosterone (6.5%), caffeine (5.6%) and theophylline (4.1%).

MAIN LIMITATIONS

Our data derive from official analyses performed in compliance with the national regulation on anti-doping controls in racehorses; information on the concentration of the detected analytes was not available. Testing only the best-placed horses does not allow for correlating drug administration and improved performance; horses with less chance of winning might slip through the control system with negative consequences on their welfare.

CONCLUSIONS

The percentage of confirmed doping violations in horse races in Italy in the 9 years (2014-2022) evaluated in this study was low (0.49 ± 0.15%). Considering the drug classes found most frequently, violations might have been more often the consequence of deliberate administration rather than accidental feed contamination.

Sample Preparation Techniques for Growth-Promoting Agents in Various Mammalian Specimen Preceding MS-Analytics

The misuse of growth-promoting drugs such as beta-2 agonists and steroids is a known problem in farming and sports competitions. Prior to the analysis of biological samples via liquid chromatography (LC)-mass spectrometry (MS) or gas chromatography (GC)-MS, sufficient sample preparation is required to reliably identify or determine the residues of drugs. In practice, broad screening methods are often used to save time and analyze as many compounds as possible. This review was conceptualized to analyze the literature from 2018 until October 2023 for sample preparation procedures applied to animal specimens before LC- or GC-MS analysis. The animals were either used in farming or sports. In the present review, solid phase extraction (SPE) was observed as the dominant sample clean-up technique for beta-2 agonists and steroids, followed by protein precipitation. For the extraction of beta-2 agonists, mixed-mode cation exchanger-based SPE phases were preferably applied, while for the steroids, various types of SPE materials were reported. Furthermore, dispersive SPE-based QuEChERs were utilized. Combinatory use of SPE and liquid-liquid extraction (LLE) was observed to cover further drug classes in addition to beta-2 agonists in broader screening methods.

Competing interests at the heart of equine sports medicine ethics: A scoping review and thematic analysis

BACKGROUND

The ethics of using horses in sport is receiving increasing attention and media scrutiny. Sports medicine ethics is an important and well-established discipline within human medicine and biomedical ethics, which has, thus far, received little application to the equine veterinary field.

OBJECTIVES

The purpose of this scoping review was to explore the existing literature on equine sports medicine ethics, to understand the current concerns and issues, and to map areas for future research.

STUDY DESIGN

Scoping review.

METHODS

Academic databases (PubMed, Web of Science, CAB abstracts) were searched to identify papers, published in English, between 2000 and 2022, that mentioned aspect(s) of the ethics of veterinary provision to the performance horse. Additionally, grey (including lay) literature was identified through global search engines to locate supplementary and opinion articles. Relevant data on article characteristics and ethical concerns were extracted and charted. Thematic analysis was employed to identify key issues.

RESULTS

A literature source of 41 papers/articles was used; of which 35 were from veterinary sources, mostly veterinary journals and conference proceedings. Several themes were identified including: competing stakeholder interests; governing bodies, rules and regulations; provision of optimal veterinary care; confidentiality; and social licence for the veterinary profession. The most commonly mentioned specific ethical concern was the use of medication in performance horses.

MAIN LIMITATIONS

In this scoping review, we have not sought to critically analyse the ethical arguments within the included literature, but rather to collate them so that an overview of ethical concerns can be established.

CONCLUSIONS

Further consideration is required as to how the veterinary profession and sporting governing bodies can support individual veterinary surgeons to strive for the highest levels of professional conduct in equine sports medicine. The veterinary profession should continue to work towards establishing processes for determining what veterinary practices are ethical, optimal, excessive, permissible and impermissible.

Genetic analysis of the equine orthologues for human CYP2D6: unraveling the complexity of the CYP2D family in horses

Introduction

Because of their importance as companion animals or as racehorses, horses can be treated with various drugs. Although it is known that drug withdrawal times can vary for each horse, pharmacogenetics for these animals has not been adequately studied and requires further development. Since CYP2D6 is responsible for the metabolism of 25-30% of drugs in humans, including some used to treat horses, a study of the CYP2D family in horses was conducted to define its genetic structure as well as its expression pattern in the liver.

Methods

Genomic DNA extracted from venous blood and mRNA from fresh liver tissue were amplified and sequenced to analyze the genomic structure, genotype, and expression of the various enzymes that are part of the equine orthologous family for CYP2D6.

Results

Amplification and sequencing of the gDNA of CYP2D50, the major CYP2D6 orthologue identified in previous studies, revealed a novel putative genomic structure for this gene compared with that reported from the EquCab3.0 assembly, including the formation of a hybrid structure similar to what happens in human CYP2D6. At the mRNA level, transcripts from six different members of the equine CYP2D family were detected in horse liver. In addition, genotyping of CYP2D50 and CYP2D82 revealed the presence of several polymorphisms, six of which result in novel, nonsynonymous amino acid changes for each of the two genes.

Discussion

This study aimed to elucidate the pharmacogenetic analysis of the CYP2D family in horses and resulted in the identification of a novel gene structure for CYP2D50, the expression of six different members of the CYP2D family in horse liver, and several novel polymorphisms for CYP2D50 and CYP2D82.

Doping control in horses in the Czech Republic in 2010-2019

The aim of this study was to evaluate data on doping controls in racehorses over a given ten-year period, primarily to identify positive findings and to summarise recommendations for the prevention of accidental contamination with prohibited substances, where appropriate. Data on doping controls of racehorses in the Czech Republic from 2010 to 2019 were obtained from the archives of the Jockey Club of the Czech Republic. For each year, the total number of horses starting at races held in the Czech Republic, the number of horses tested, and the results of the doping controls were determined. Data on the type of samples, positive findings and statements from responsible persons about the cause of the positive finding were recorded. During the monitoring period, 11,852 horses competed in races in the Czech Republic and 641 of them underwent a doping control. Blood was taken from 356 horses as the sample for testing and urine was collected from 285 horses. A total of 13 positive findings (2.03% of the 641 tested) were found during the period, namely of morphine, caffeine, theobromine, omeprazole sulphide, furosemide, clenbuterol, norketamine, ritalinic acid, dexamethasone, flunixin, hydroxylidocaine and oripavine. The most common cause, in a total of seven horses, was confirmed as suspected feed contamination. Prevention of positive doping results in our circumstances should therefore be directed primarily towards compliance with proper feed and stable management.

Psychosocial aspects of sports medicine in pediatric athletes: Current concepts in the 21st century

Behavioral aspects of organized sports activity for pediatric athletes are considered in a world consumed with winning at all costs. In the first part of this treatise, we deal with a number of themes faced by our children in their sports play. These concepts include the lure of sports, sports attrition, the mental health of pediatric athletes (i.e., effects of stress, anxiety, depression, suicide in athletes, ADHD and stimulants, coping with injuries, drug use, and eating disorders), violence in sports (i.e., concepts of the abused athlete including sexual abuse), dealing with supervisors (i.e., coaches, parents), peers, the talented athlete, early sports specialization and sports clubs. In the second part of this discussion, we cover ergolytic agents consumed by young athletes in attempts to win at all costs. Sports doping agents covered include anabolic steroids (anabolic-androgenic steroids or AAS), androstenedione, dehydroepiandrostenedione (DHEA), human growth hormone (hGH; also its human recombinant homologue: rhGH), clenbuterol, creatine, gamma hydroxybutyrate (GHB), amphetamines, caffeine and ephedrine. Also considered are blood doping that includes erythropoietin (EPO) and concepts of gene doping. In the last section of this discussion, we look at disabled pediatric athletes that include such concepts as athletes with spinal cord injuries (SCIs), myelomeningocele, cerebral palsy, wheelchair athletes, and amputee athletes; also covered are pediatric athletes with visual impairment, deafness, and those with intellectual disability including Down syndrome. In addition, concepts of autonomic dysreflexia, boosting and atlantoaxial instability are emphasized. We conclude that clinicians and society should protect our precious pediatric athletes who face many challenges in their involvement with organized sports in a world obsessed with winning. There is much we can do to help our young athletes find benefit from sports play while avoiding or blunting negative consequences of organized sport activities.